Is LGVN or FTLF more profitable?

FitLife Brands has a net margin of 6.64% compared to Longeveron's net margin of -1,844.49%. FitLife Brands' return on equity of 18.31% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,844.49% -202.41% -140.67% FitLife Brands 6.64% 18.31% 8.21%

Does the media prefer LGVN or FTLF?

In the previous week, Longeveron had 4 more articles in the media than FitLife Brands. MarketBeat recorded 6 mentions for Longeveron and 2 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.93 beat Longeveron's score of 0.85 indicating that FitLife Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FitLife Brands 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PEPG or LGVN?

Longeveron has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Longeveron $1.20M 20.64 -$22.70M -$1.13 N/A

Is PEPG or LGVN more profitable?

PepGen has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. PepGen's return on equity of -59.89% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Longeveron -1,844.49% -202.41% -140.67%

Do analysts prefer LGVN or AIFC?

Longeveron presently has a consensus target price of $5.50, suggesting a potential upside of 591.82%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, LGVN or AIFC?

Longeveron has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Longeveron $1.20M 20.64 -$22.70M -$1.13 N/A ALT5 Sigma $24.84M 4.34 -$344.51M N/A N/A

Is LGVN or AIFC more profitable?

Longeveron has a net margin of -1,844.49% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,844.49% -202.41% -140.67% ALT5 Sigma -2,483.94% -68.25% -62.43%

Does the media refer more to LGVN or AIFC?

In the previous week, Longeveron had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 6 mentions for Longeveron and 5 mentions for ALT5 Sigma. Longeveron's average media sentiment score of 0.85 beat ALT5 Sigma's score of 0.38 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ICCC or LGVN?

Longeveron has a consensus price target of $5.50, indicating a potential upside of 591.82%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation and earnings, ICCC or LGVN?

ImmuCell has higher revenue and earnings than Longeveron. ImmuCell is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.14 -$1.04M -$0.06 N/A Longeveron $1.20M 20.64 -$22.70M -$1.13 N/A

Is ICCC or LGVN more profitable?

ImmuCell has a net margin of -1.82% compared to Longeveron's net margin of -1,844.49%. ImmuCell's return on equity of -1.88% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% Longeveron -1,844.49% -202.41% -140.67%

Does the media favor ICCC or LGVN?

In the previous week, Longeveron had 4 more articles in the media than ImmuCell. MarketBeat recorded 6 mentions for Longeveron and 2 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.94 beat Longeveron's score of 0.85 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Longeveron 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATRA or LGVN?

In the previous week, Longeveron had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 6 mentions for Longeveron and 3 mentions for Atara Biotherapeutics. Longeveron's average media sentiment score of 0.85 beat Atara Biotherapeutics' score of 0.51 indicating that Longeveron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Longeveron 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Longeveron (LGVN) Competitors

$0.80 +0.01 (+1.58%)

As of 12:15 PM Eastern

Compare

LGVN vs. FTLF, PEPG, AIFC, ICCC, and ATRA

Should you buy Longeveron stock or one of its competitors? MarketBeat compares Longeveron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Longeveron include FitLife Brands (FTLF), PepGen (PEPG), ALT5 Sigma (AIFC), ImmuCell (ICCC), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

How does Longeveron compare to FitLife Brands?

Longeveron (NASDAQ:LGVN) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

FitLife Brands has a net margin of 6.64% compared to Longeveron's net margin of -1,844.49%. FitLife Brands' return on equity of 18.31% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
FitLife Brands	6.64%	18.31%	8.21%

Longeveron has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

10.0% of Longeveron shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 61.4% of FitLife Brands shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Longeveron had 4 more articles in the media than FitLife Brands. MarketBeat recorded 6 mentions for Longeveron and 2 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.93 beat Longeveron's score of 0.85 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FitLife Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FitLife Brands has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	20.64	-$22.70M	-$1.13	N/A
FitLife Brands	$81.46M	1.29	$6.33M	$0.60	18.66

Longeveron currently has a consensus target price of $5.50, suggesting a potential upside of 591.82%. FitLife Brands has a consensus target price of $21.50, suggesting a potential upside of 92.03%. Given Longeveron's higher probable upside, equities research analysts plainly believe Longeveron is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

FitLife Brands beats Longeveron on 10 of the 14 factors compared between the two stocks.

How does Longeveron compare to PepGen?

PepGen (NASDAQ:PEPG) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

PepGen has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market.

PepGen currently has a consensus target price of $11.60, indicating a potential upside of 670.25%. Longeveron has a consensus target price of $5.50, indicating a potential upside of 591.82%. Given PepGen's stronger consensus rating and higher probable upside, equities analysts clearly believe PepGen is more favorable than Longeveron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

PepGen has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. PepGen's return on equity of -59.89% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Longeveron	-1,844.49%	-202.41%	-140.67%

58.0% of PepGen shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Longeveron had 5 more articles in the media than PepGen. MarketBeat recorded 6 mentions for Longeveron and 1 mentions for PepGen. PepGen's average media sentiment score of 0.94 beat Longeveron's score of 0.85 indicating that PepGen is being referred to more favorably in the media.

Company	Overall Sentiment
PepGen	Positive
Longeveron	Positive

Longeveron has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Longeveron	$1.20M	20.64	-$22.70M	-$1.13	N/A

Summary

PepGen beats Longeveron on 9 of the 15 factors compared between the two stocks.

How does Longeveron compare to ALT5 Sigma?

Longeveron (NASDAQ:LGVN) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Longeveron has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	20.64	-$22.70M	-$1.13	N/A
ALT5 Sigma	$24.84M	4.34	-$344.51M	N/A	N/A

10.0% of Longeveron shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Longeveron has a net margin of -1,844.49% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Longeveron presently has a consensus target price of $5.50, suggesting a potential upside of 591.82%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Longeveron has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

In the previous week, Longeveron had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 6 mentions for Longeveron and 5 mentions for ALT5 Sigma. Longeveron's average media sentiment score of 0.85 beat ALT5 Sigma's score of 0.38 indicating that Longeveron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Longeveron beats ALT5 Sigma on 10 of the 14 factors compared between the two stocks.

How does Longeveron compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ImmuCell has higher revenue and earnings than Longeveron. ImmuCell is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.14	-$1.04M	-$0.06	N/A
Longeveron	$1.20M	20.64	-$22.70M	-$1.13	N/A

ImmuCell has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market.

ImmuCell has a net margin of -1.82% compared to Longeveron's net margin of -1,844.49%. ImmuCell's return on equity of -1.88% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Longeveron	-1,844.49%	-202.41%	-140.67%

In the previous week, Longeveron had 4 more articles in the media than ImmuCell. MarketBeat recorded 6 mentions for Longeveron and 2 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.94 beat Longeveron's score of 0.85 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Longeveron	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Longeveron has a consensus price target of $5.50, indicating a potential upside of 591.82%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

ImmuCell beats Longeveron on 9 of the 16 factors compared between the two stocks.

How does Longeveron compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Longeveron had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 6 mentions for Longeveron and 3 mentions for Atara Biotherapeutics. Longeveron's average media sentiment score of 0.85 beat Atara Biotherapeutics' score of 0.51 indicating that Longeveron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Longeveron	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 7.4% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market.

Atara Biotherapeutics has a net margin of -40.91% compared to Longeveron's net margin of -1,844.49%. Atara Biotherapeutics' return on equity of -79.12% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Longeveron	-1,844.49%	-202.41%	-140.67%

Atara Biotherapeutics has higher revenue and earnings than Longeveron. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.78	$32.69M	-$0.67	N/A
Longeveron	$1.20M	20.64	-$22.70M	-$1.13	N/A

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential downside of 8.57%. Longeveron has a consensus price target of $5.50, indicating a potential upside of 591.82%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Atara Biotherapeutics beats Longeveron on 9 of the 16 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGVN vs. The Competition

Export

Metric	Longeveron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.76M	$3.40B	$6.50B	$12.37B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.70	20.08	24.01	24.71
Price / Sales	20.64	326.19	540.55	165.59
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	3.18	8.11	10.55	6.85
Net Income	-$22.70M	$23.89M	$3.56B	$337.45M
7 Day Performance	5.44%	3.36%	1.54%	2.70%
1 Month Performance	18.57%	1.34%	2.48%	4.60%
1 Year Performance	-38.85%	46.46%	26.49%	32.81%

Longeveron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGVN Longeveron	2.9544 of 5 stars	$0.80 +1.6%	$5.50 +591.8%	-39.8%	$24.76M	$1.20M	N/A	20	Analyst Upgrade Gap Up
FTLF FitLife Brands	4.5247 of 5 stars	$10.22 -1.4%	$21.50 +110.4%	-21.4%	$95.97M	$81.46M	16.92	20
PEPG PepGen	2.6561 of 5 stars	$1.38 +2.2%	$11.60 +740.6%	+2.8%	$95.45M	N/A	N/A	30
AIFC ALT5 Sigma	0.2909 of 5 stars	$0.68 +3.3%	N/A	-93.5%	$94.91M	$24.84M	N/A	170	Gap Up
ICCC ImmuCell	0.6795 of 5 stars	$9.77 +0.7%	N/A	+49.4%	$88.42M	$27.64M	N/A	70	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGVN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longeveron (LGVN) Competitors

LGVN vs. FTLF, PEPG, AIFC, ICCC, and ATRA

How does Longeveron compare to FitLife Brands?

Summary

How does Longeveron compare to PepGen?

Summary

How does Longeveron compare to ALT5 Sigma?

Summary

How does Longeveron compare to ImmuCell?

Summary

How does Longeveron compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longeveron (LGVN) Competitors

LGVN vs. FTLF, PEPG, AIFC, ICCC, and ATRA

How does Longeveron compare to FitLife Brands?

Is LGVN or FTLF more profitable?

Which has more volatility and risk, LGVN or FTLF?

Do institutionals and insiders have more ownership in LGVN or FTLF?

Does the media prefer LGVN or FTLF?

Which has better valuation and earnings, LGVN or FTLF?

Do analysts rate LGVN or FTLF?

Summary

How does Longeveron compare to PepGen?

Which has more risk & volatility, PEPG or LGVN?

Do analysts rate PEPG or LGVN?

Is PEPG or LGVN more profitable?

Do institutionals & insiders have more ownership in PEPG or LGVN?

Does the media refer more to PEPG or LGVN?

Which has better earnings & valuation, PEPG or LGVN?

Summary

How does Longeveron compare to ALT5 Sigma?

Which has higher earnings and valuation, LGVN or AIFC?

Do insiders & institutionals hold more shares of LGVN or AIFC?

Is LGVN or AIFC more profitable?

Do analysts prefer LGVN or AIFC?

Which has more risk and volatility, LGVN or AIFC?

Does the media refer more to LGVN or AIFC?

Summary

How does Longeveron compare to ImmuCell?

Do institutionals and insiders believe in ICCC or LGVN?

Which has higher valuation and earnings, ICCC or LGVN?

Which has more risk & volatility, ICCC or LGVN?

Is ICCC or LGVN more profitable?

Does the media favor ICCC or LGVN?

Do analysts recommend ICCC or LGVN?

Summary

How does Longeveron compare to Atara Biotherapeutics?

Does the media favor ATRA or LGVN?

Do institutionals and insiders hold more shares of ATRA or LGVN?

Which has more volatility and risk, ATRA or LGVN?

Is ATRA or LGVN more profitable?

Which has better earnings & valuation, ATRA or LGVN?

Do analysts prefer ATRA or LGVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools